Clinofibrate
![]() | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C28H36O6 |
| Molar mass | 468.590 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
Clinofibrate (INN; trade name Lipoclin) is pharmaceutical drug of the fibrate class that is used for managing hyperlipidemia and associated conditions.[1] It is sold and marketed in Japan.[2]
Chemically, it is a derivative of bisphenol Z.[3]
Synthesis
The condensation between cyclohexanone (1) and phenol (2) gives bisphenol Z (3).[4] This is treated with chloroform and methyl ethyl ketone (MEK) in the presence of base. The resulting Bargellini reaction gives clinofibrate (4).[5]

Synthesis of clinofibrate
References
- ^ "What is Clinofibrate used for?". Synapse. 14 June 2024.
- ^ "Clinofibrate". DrugBank.
- ^ Takeuchi N, Kukita H, Kajiyama G, Fujiyama M, Ishikawa K, Miki H, Mishima T, Murata K, Asano T (April 1982). "Effect of clinofibrate, a new hypolipidemic agent, on biliary and serum lipids in patients with hyperlipidemia". Atherosclerosis. 42 (2–3): 129–39. doi:10.1016/0021-9150(82)90145-9. PMID 7073798.
- ^ Patil LS, Suryawanshi VS, Pawar OB, Shinde ND (2011). "An Improved, Highly Efficient Method for the Synthesis of Bisphenols". e-Journal of Chemistry. 8 (4): 2016–2019. doi:10.1155/2011/372673.
- ^ US 3716583, Nakamura Y, Aono S, Agatsuma K, Tanaka Y, "Phenoxy carboxylic acid derivative", issued 13 February 1973, assigned to Sumitomo Chemical Company
